Literature DB >> 17190859

A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML.

Bas J Wouters, Irene Louwers, Peter J M Valk, Bob Löwenberg, Ruud Delwel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17190859     DOI： 10.1182/blood-2006-08-042325

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

1.  Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms.

Authors:  Thomas Ernst; Andrew Chase; Katerina Zoi; Katherine Waghorn; Claire Hidalgo-Curtis; Joannah Score; Amy Jones; Francis Grand; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

2.  NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.

Authors:  Patricia Rubio; B Campos; J A Digiorge; M S Gallego; A Medina; J G Rossi; M S Felice; C N Alonso
Journal:  Int J Hematol       Date:  2016-07-19       Impact factor: 2.490

3.  Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Authors:  Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Tamara Vukosavljevic; Peter Paschka; Susan P Whitman; Christian Langer; Claudia D Baldus; Chang-Gong Liu; Amy S Ruppert; Bayard L Powell; Andrew J Carroll; Michael A Caligiuri; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Authors:  F Theis; A Corbacioglu; V I Gaidzik; P Paschka; D Weber; L Bullinger; M Heuser; A Ganser; F Thol; B Schlegelberger; G Göhring; C-H Köhne; U Germing; P Brossart; H-A Horst; D Haase; K Götze; M Ringhoffer; W Fiedler; D Nachbaur; T Kindler; G Held; M Lübbert; M Wattad; H R Salih; J Krauter; H Döhner; R F Schlenk; K Döhner
Journal:  Leukemia       Date:  2016-07-04       Impact factor: 11.528

5.  Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.

Authors:  Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Martin Zimmermann; Justine K Peeters; Peter J M Valk; Brian V Balgobind; Edwin Sonneveld; Gertjan J L Kaspers; Eveline S J M de Bont; Jan Trka; Andre Baruchel; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; C Michel Zwaan
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

6.  Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

Authors:  Bas J Wouters; Bob Löwenberg; Claudia A J Erpelinck-Verschueren; Wim L J van Putten; Peter J M Valk; Ruud Delwel
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

7.  Molecular study of CEBPA in familial hematological malignancies.

Authors:  R El Abed; V Bourdon; L Huiart; F Eisinger; A Khelif; M Frenay; P Gesta; L Demange; H Dreyfus; V Bonadona; C Dugast; H Zattara; L Faivre; T Noguchi; R Sauvan; Z Soua; H Sobol
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

8.  A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia.

Authors:  Jeung-Yeal Ahn; Katie Seo; Olga Weinberg; Scott D Boyd; Daniel A Arber
Journal:  J Mol Diagn       Date:  2009-06-12       Impact factor: 5.568

9.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

Authors:  Phoenix A Ho; Todd A Alonzo; Robert B Gerbing; Jessica Pollard; Derek L Stirewalt; Craig Hurwitz; Nyla A Heerema; Betsy Hirsch; Susana C Raimondi; Beverly Lange; Janet L Franklin; Jerald P Radich; Soheil Meshinchi
Journal:  Blood       Date:  2009-03-20       Impact factor: 22.113

10.  Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.

Authors:  T Pabst; M Eyholzer; J Fos; B U Mueller
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.